{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:06:21Z","timestamp":1790287581833,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.intimp.2025.116129","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T21:58:29Z","timestamp":1767131909000},"page":"116129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["circSERINC3 facilitates STAT3-CDK5 crosstalk to orchestrate immunosuppressive microenvironments in pancreatic Cancer"],"prefix":"10.1016","volume":"171","author":[{"given":"Min","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xintao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianlan","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.intimp.2025.116129_bb0005","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","article-title":"The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities","volume":"17","author":"Ho","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2025.116129_bb0010","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.ccell.2020.08.004","article-title":"Challenges and opportunities for pancreatic Cancer immunotherapy","volume":"38","author":"Bear","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2025.116129_bb0015","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3389\/fonc.2018.00649","article-title":"Quantitative characterization of CD8+ T cell clustering and spatial heterogeneity in solid Tumors","volume":"8","author":"Gong","year":"2018","journal-title":"Front. Oncol."},{"issue":"24","key":"10.1016\/j.intimp.2025.116129_bb0020","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1158\/0008-5472.CAN-23-3596","article-title":"CircRREB1 mediates metabolic reprogramming and stemness maintenance to facilitate pancreatic ductal adenocarcinoma progression","volume":"84","author":"Rong","year":"2024","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.intimp.2025.116129_bb0025","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1038\/s41418-023-01171-8","article-title":"Circular RNA circRILPL1 promotes nasopharyngeal carcinoma malignant progression by activating the hippo-YAP signaling pathway","volume":"30","author":"Wu","year":"2023","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.intimp.2025.116129_bb0030","article-title":"SenExo-cCCT2 reprograms senescence response and anti-tumor immunity following FOLFIRINOX chemotherapy in pancreatic ductal adenocarcinoma","volume":"12","author":"Zhu","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.intimp.2025.116129_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101240","article-title":"Targeting cTRIP12 counteracts ferroptosis resistance and augments sensitivity to immunotherapy in pancreatic cancer","volume":"81","author":"Lin","year":"2025","journal-title":"Drug Resist. Updat."},{"issue":"12","key":"10.1016\/j.intimp.2025.116129_bb0040","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.neo.2021.10.003","article-title":"STAT3 as a mediator of oncogenic cellular metabolism: pathogenic and therapeutic implications","volume":"23","author":"To\u0161i\u0107","year":"2021","journal-title":"Neoplasia"},{"issue":"2","key":"10.1016\/j.intimp.2025.116129_bb0045","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1365-2443.2011.01575.x","article-title":"Phospho-Ser727 of STAT3 regulates STAT3 activity by enhancing dephosphorylation of phospho-Tyr705 largely through TC45","volume":"17","author":"Wakahara","year":"2012","journal-title":"Genes Cells"},{"issue":"4","key":"10.1016\/j.intimp.2025.116129_bb0050","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.3892\/ijo.2016.3632","article-title":"The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6\/JAK\/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer","volume":"49","author":"Zhang","year":"2016","journal-title":"Int. J. Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2025.116129_bb0055","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1007\/s10147-017-1161-7","article-title":"PD-L1 induced by IFN-\u03b3 from tumor-associated macrophages via the JAK\/STAT3 and PI3K\/AKT signaling pathways promoted progression of lung cancer","volume":"22","author":"Zhang","year":"2017","journal-title":"Int. J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.intimp.2025.116129_bb0060","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41576-019-0158-7","article-title":"The biogenesis, biology and characterization of circular RNAs","volume":"20","author":"Kristensen","year":"2019","journal-title":"Nat. Rev. Genet."},{"issue":"1","key":"10.1016\/j.intimp.2025.116129_bb0065","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12943-023-01759-1","article-title":"Exosome-derived circCCAR1 promotes CD8+T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma","volume":"22","author":"Hu","year":"2023","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2025.116129_bb0070","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.immuni.2022.12.008","article-title":"Microenvironment-driven metabolic adaptations guiding CD8(+) T cell anti-tumor immunity","volume":"56","author":"Park","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2025.116129_bb0075","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.790113","article-title":"Immunological classification of tumor types and advances in precision combination immunotherapy","volume":"13","author":"Ren","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.116129_bb0080","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13046-019-1161-8","article-title":"Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK\/STAT3\/PD-L1 pathway","volume":"38","author":"Shen","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2025.116129_bb0085","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol. Cancer"},{"issue":"5","key":"10.1016\/j.intimp.2025.116129_bb0090","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.tig.2023.01.009","article-title":"miRNA biogenesis and inherited disorders: clinico-molecular insights","volume":"39","author":"Pelletier","year":"2023","journal-title":"Trends Genet."},{"issue":"1","key":"10.1016\/j.intimp.2025.116129_bb0095","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12943-023-01895-8","article-title":"CDK5: an oncogene or an anti-oncogene: location location location","volume":"22","author":"Nikhil","year":"2023","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2025.116129_bb0100","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12943-020-01286-3","article-title":"Circular RNA: metabolism, functions and interactions with proteins","volume":"19","author":"Zhou","year":"2020","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2025.116129_bb0105","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10565-025-10038-2","article-title":"The key regulator circPDE3B promotes arsenic-induced bladder carcinogenesis by affecting STAT3 and NF-\u03baB stability","volume":"41","author":"Gao","year":"2025","journal-title":"Cell Biol. Toxicol."},{"issue":"1","key":"10.1016\/j.intimp.2025.116129_bb0110","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0960-9822(99)00268-7","article-title":"Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR","volume":"10","author":"Yokogami","year":"2000","journal-title":"Curr. Biol."},{"issue":"4","key":"10.1016\/j.intimp.2025.116129_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112316","article-title":"CDK5-PRMT1-WDR24 signaling cascade promotes mTORC1 signaling and tumor growth","volume":"42","author":"Yin","year":"2023","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.intimp.2025.116129_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13010101","article-title":"The role of CDK5 in tumours and tumour microenvironments","volume":"13","author":"Do","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"6297","key":"10.1016\/j.intimp.2025.116129_bb0125","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.aae0477","article-title":"Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity","volume":"353","author":"Dorand","year":"2016","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.intimp.2025.116129_bb0130","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12010124","article-title":"Energy metabolism in Cancer: the roles of STAT3 and STAT5 in the regulation of metabolism-related genes","volume":"12","author":"Valle-Mendiola","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.intimp.2025.116129_bb0135","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13046-024-02949-5","article-title":"Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery","volume":"43","author":"Hu","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925021186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925021186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T20:12:19Z","timestamp":1768335139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925021186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":27,"alternative-id":["S1567576925021186"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.116129","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"circSERINC3 facilitates STAT3-CDK5 crosstalk to orchestrate immunosuppressive microenvironments in pancreatic Cancer","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.116129","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116129"}}